Skip to content
Open access

CAMKV kinase drives neuroblastoma growth and acts as a novel therapeutic target

Sep 2026 · Journal of Experimental Medicine · Vol 223 · 0 citations
Medicine

TL;DR

This work identifies CaM kinase-like vesicle-associated protein (CAMKV) as a MYCN/MYC-regulated effector of NB pathogenesis and establishes CAMKV as a central signaling hub that coordinates metabolic and proliferative pathways.

Abstract

High-risk (HR) neuroblastoma (NB) remains a leading cause of pediatric cancer mortality, frequently driven by MYCN amplification or MYC overexpression. Despite their central role, direct pharmacological targeting of these transcription factors remains clinically challenging. Here, we identify CaM kinase-like vesicle-associated protein (CAMKV) as a MYCN/MYC-regulated effector of NB pathogenesis. Although previously classified as a non-functional pseudokinase, we demonstrate that CAMKV possesses intrinsic kinase activity that is essential for tumor growth. Analysis of patient datasets and primary tumors shows that elevated CAMKV expression correlates with advanced disease stage and poor overall survival. Through integrated transcriptomics, ChIP-seq, and phosphoproteomics, we establish CAMKV as a central signaling hub that coordinates metabolic and proliferative pathways. Both genetic depletion and small-molecule inhibition of CAMKV significantly impair NB cell proliferation in vitro and suppress tumor growth in vivo. Collectively, our findings establish CAMKV as a unifying therapeutic vulnerability and highlight this functional kinase as a promising target for translational development in HR NB.

Read PDF

Similar papers

Open access Sep 2026

MYL9 silencing inhibits proliferation and migration of lung adenocarcinoma cells: a potential therapeutic target

Background Myosin light chain 9 (MYL9), a regulatory light chain of myosin II, plays a crucial role in cytoskeletal dynamics and has been associated with tumor progression in multiple malignancies. However, its role in lung adenocarcinoma (LUAD) remains poorly characterized. Despite recent advances in treatment, the pr...

Xiang Tan, Ye Chen, Min-Lian Nong et al. · 0 citations
Open access Nov 2026

Targeting a MYC-directed metabolic vulnerability sensitizes tyrosine kinase inhibitor therapy with selectivity

A key strategy for precision therapy lies in identifying and targeting tumor cell-specific metabolic vulnerabilities to develop effective combination treatments. In this study, we demonstrate that vandetanib, a multi-kinase inhibitor, acts as a potent transcriptional repressor of the serine synthesis pathway (SSP) in...

Yan Zhou, Yin-Yin Xie, Fu-Hui Wang et al. · 0 citations
Open access Nov 2026

Protein Tyrosine Phosphatase 4A3 (PTP4A3) as a Prognostic Biomarker and Pharmacological Target in Acute Myeloid Leukemia

Acute myeloid leukemia (AML) represents a critical focus for biomarker research, given its high mortality, rapid progression, substantial treatment resistance, and marked genetic heterogeneity. The present study identifies PTP4A3 as a relevant molecular determinant in the disease, linking its overexpression to advers...

Natália Sudan Parducci, Maria Fernanda Lopes Carvalho, I. C. Santos et al. · 0 citations
Review Oct 2026

RIPK1 kinase and scaffold activities in tumor cell fate and therapy.

Receptor-interacting protein kinase 1 (RIPK1) plays a pivotal role in regulating cell survival and death, thereby exerting complex and multifaceted functions in the initiation and progression of cancer. Its expression is frequently dysregulated across diverse malignancies and correlates strongly with poor prognosis, hi...

Jing-Yu Luo, Shu-Ya Song, Ze-Kun Li et al. · 0 citations
Review Open access Oct 2026

SHP2 in Cancer: From Tumor Biology to Therapeutic Targeting.

SHP2 is a tyrosine phosphatase that mediates intracellular signaling downstream of transmembrane receptors regulated by a pair of src homology 2 (SH2) domains. Its overexpression and mutation are pivotal in driving tumor progression by influencing various cancer's fundamental characteristics, such as metastasis, DNA re...

Maryam Jama, M. Overduin, K. Barakat · 0 citations
Open access Oct 2026

Exploration of Alternative Approaches to Citron Kinase Inhibition for Glioblastoma Treatment

Glioblastoma (GBM) remains a highly aggressive brain tumor with limited therapeutic options, highlighting the need to identify novel tumor vulnerabilities. Citron kinase (CITK), a protein involved in cytokinesis and genome stability, is required for the proliferation and survival of neural progenitors and has previousl...

Alessia Ferraro, L. Lazzerini, Giorgia Iegiani et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.